Copyright
©The Author(s) 2019.
World J Clin Oncol. Oct 24, 2019; 10(10): 318-339
Published online Oct 24, 2019. doi: 10.5306/wjco.v10.i10.318
Published online Oct 24, 2019. doi: 10.5306/wjco.v10.i10.318
Clinical trial identifier | Title | Objective |
NCT01185639 | Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-Small Cell Lung Cancer | To evaluate the efficacy of SBRT in oligometastatic NSCLC patients who achieve partial response or stable disease after 4 cycles of ChT. The hypothesis is that SBRT after 4 cycles of ChT is feasible, safe, with good local control, and improves time to progression |
NCT 02314364 | A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC | To evaluate SBRT in patients with stage 4 NSCLC and EGFR, ALK, or ROS1 mutations who have been treated with erlotinib, gefitinib, or other targeted drugs |
NCT03275597 | Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition | To evaluate the safety and tolerability of SBRT combined with durvalumab and tremelimumab for oligometastatic NSCLC |
NCT02975609 | Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer | To compare the efficacy and safety of SBRT vs conventional radiotherapy after response to 4-6 cycles of chemotherapy. Outcome measures for both groups include PFS, OS, and adverse effects |
NCT03808337 | Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease | To determine if SBRT to all oligometastatic lesions can extend time to progression |
NCT02417662 | Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer (SARON) | Phase III study of efficacy and safety in oligometastatic NSCLC patients comparing conventional ChT alone to ChT plus conventional radiotherapy to the primary tumor and SBRT to the metastases |
- Citation: Couñago F, Luna J, Guerrero LL, Vaquero B, Guillén-Sacoto MC, González-Merino T, Taboada B, Díaz V, Rubio-Viqueira B, Díaz-Gavela AA, Marcos FJ, del Cerro E. Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions. World J Clin Oncol 2019; 10(10): 318-339
- URL: https://www.wjgnet.com/2218-4333/full/v10/i10/318.htm
- DOI: https://dx.doi.org/10.5306/wjco.v10.i10.318